Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe latest version shows Revision: v3.6.3, replacing the previous v3.6.2. This indicates a platform update rather than changes to study content.SummaryDifference0.0%

- Check38 days agoChange DetectedThe page history now records a new revision (v3.6.2) and removes an older revision (v3.6.0), updating the version history to reflect the latest state of the page.SummaryDifference0.0%

- Check53 days agoChange DetectedNew navigation items 'Check who can join' and 'Find Contact Information' appear on the study record history. The revision label updates to Revision: v3.6.0, replacing the previous v3.5.5.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page history shows Revision: v3.5.5 replacing the previous v3.5.4, indicating a small update to the record's metadata.SummaryDifference0.0%

- Check81 days agoChange DetectedA new page revision label v3.5.4 was added to the history, replacing the previous v3.5.3. This indicates an update to the study record's revision history.SummaryDifference0.0%

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.